Memorial Sloan Kettering Cancer Center: Melanoma trials

The registry lists 63 Melanoma studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 4 are open to participants now and 16 have results posted.

Early Phase 1 1Phase 1 17Phase 2 24Phase 3 2No phase 20(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Using an Artificial Intelligence (AI) Tool for Melanoma DiagnosisRecruitingNCT07890415Phase 3
• A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor CancerRecruitingNCT05859074Phase 1
• A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft TissueRecruitingNCT05837767Not applicable
• A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or AngiosarcomaRecruitingNCT05607095Phase 1
• A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid TumorsCompletedNCT02819843Phase 2Results posted
• Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)CompletedNCT02553642Phase 2Results posted
• BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 MutationCompletedNCT01894672Phase 2Results posted
• Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K MutationCompletedNCT01682213Phase 2Results posted
• Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K MutationTerminatedNCT01474551Phase 2Results posted
• Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The ExtremityCompletedNCT01323517Phase 2Results posted
• Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) ProtectionCompletedNCT01004952Results posted
• Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic MelanomaCompletedNCT00885534Phase 2Results posted
• Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous MelanomaCompletedNCT00597272Not applicableResults posted
• Treatment With Intravitreal Avastin for Large Uveal MelanomasCompletedNCT00596362Not applicableResults posted
• Phase II Trial of Extended-Dosing Temozolomide in Patients With MelanomaCompletedNCT00591370Phase 2Results posted
• Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical ResectionCompletedNCT00588341Phase 2Results posted
• Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain MetastasesCompletedNCT00587964Phase 2Results posted
• Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or MelanomaCompletedNCT00462982Phase 2Results posted
• Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal CancerCompletedNCT00445965Phase 2Results posted
• Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV MelanomaCompletedNCT00398073Phase 1Results posted
• A Study of IO102/IO103, Nivolumab, and Relatlimab in People With MelanomaActive, not recruitingNCT05912244Phase 2
• A Study of LN-144 in People With Metastatic Melanoma to the BrainActive, not recruitingNCT05640193Phase 1
• A Study of Tumor Imaging With Multispectral Optoacoustic TomographyActive, not recruitingNCT05488483
• CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With MelanomaActive, not recruitingNCT05289193Phase 2
• A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With CancerActive, not recruitingNCT05053230Not applicable
• Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal MelanomaCompletedNCT03922880Phase 1
• A Study To See Why Patients Agree To or Decline To Have Treatment After SurgeryCompletedNCT03843593
• Treating Patients With Melanoma and ALK Alterations With EnsartinibActive, not recruitingNCT03420508Phase 2
• Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint InhibitorsCompletedNCT03326973
• Pfizer PF-06688992 in Patients With Stage III or Stage IV MelanomaCompletedNCT03159117Phase 1
• A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination ImmunotherapyActive, not recruitingNCT03122522Phase 2
• Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated MelanomaCompletedNCT03026517Phase 1
• PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot StudyActive, not recruitingNCT02307630Not applicable
• PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-DerivativeCompletedNCT01916135Phase 1
• Clinical and Histopathologic Characteristics of BAP1 MutationsCompletedNCT01773655
• Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in MelanomaCompletedNCT01456104Phase 1
• PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing StudyActive, not recruitingNCT01266096Not applicable
• Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation TherapyActive, not recruitingNCT01223248Phase 3
• Illness Related Distress in Women With Clinically Localized Cutaneous MelanomaCompletedNCT00745862
• Immune Responses To Antigen-Bearing Dendritic Cells in Patients With MalignancyCompletedNCT00700167Phase 1
• Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA VaccinesCompletedNCT00698100Phase 1
• Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune ResponseCompletedNCT00680589Phase 1
• Differential Risks for Melanoma: p16 and DNA RepairCompletedNCT00615095
• Health Communication in FamiliesCompletedNCT00597961
• A Model for Genetic Susceptibility: MelanomaActive, not recruitingNCT00591500
• Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With MelanomaCompletedNCT00588198
• Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal TractActive, not recruitingNCT00582647
• Intraoperative Mapping of Regional Lymphatics Draining the Primary Site of Melanoma Using Isosulfan BlueCompletedNCT00581698
• Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And ImmunityCompletedNCT00580060Early Phase 1
• Health Behaviors, Surveillance, Psychosocial Factors, and Family ConcernsCompletedNCT00518050
• An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing RadiationCompletedNCT00132704
• Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV MelanomaCompletedNCT00104845Phase 1
• Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV MelanomaWithdrawnNCT00085579Phase 2
• Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV MelanomaCompletedNCT00072345Phase 2
• Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00027742Phase 2
• Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00005815Phase 1/2
• Vaccine Therapy in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00005633Phase 1
• Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By SurgeryCompletedNCT00004250Phase 2
• PET and CT Scans to Evaluate Patients With Stage III or Stage IV MelanomaCompletedNCT00004152Phase 2
• Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic CancerCompletedNCT00004065Phase 1
• Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced MelanomaCompletedNCT00003362Phase 2
• Combination Chemotherapy in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00003346Phase 2
• Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal CancerCompletedNCT00003022Phase 1